Tzield® (teplizumab-mzwv)
for Diabetes Type 1

Tzield (teplizumab-mzwv) slows the progression from stage 2 to stage 3 type 1 diabetes by preventing the immune system from attacking insulin-producing beta cells. This delays insulin dependence, reduces blood sugar monitoring needs, and lowers the risk of diabetic ketoacidosis. As an anti-CD3-directed antibody, Tzield helps regulate the immune response against beta cells.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Diabetes Type 1